The National Forum released the following statement about the Institute for Clinical and Economic Review’s (ICER’s) announcement today that it will conduct value assessments of inclisiran and bempadoic acid, two new treatments for high cholesterol. The Value & Access Steering Committee (VASC), convened by the National Forum and representing patients, clinical providers, public health, payers and purchasers, has provided input to ICER on several of its assessments. We are pleased that ICER continues to seek input from the VASC and National Forum members.
Analyses of the health and economic impacts of therapies can be valuable to society when they are evidence-based and include input from different stakeholders. The National Forum and the Value & Access Steering Committee will collaborate with ICER to ensure the inclusion of input from patients, clinical providers, public health, payers and purchasers in ICER’s review of new cholesterol-lowering therapies, inclisiran and bempadoic acid.
Click here to see ICER’s announcement.
The National Forum is a nonprofit organization with over 100 public, private and nonprofit sector members. Its mission is to lead and encourage collaborative action among stakeholders committed to heart disease and stroke prevention. The National Forum’s overarching goal is to eliminate cardiovascular health disparities and achieve health equity.
